PENTAX and Vedkang Form JV for Endoscopic Device Development
PENTAX Medical and Jiangsu Vedkang Medical Science and Technology of HOYA Group have formed a Joint Venture (JV) to create flexible single-use endoscopic medical therapy products.
The joint venture, named PENTAX Medical Therapeutics (Jiangsu), will leverage PENTAX’s commercialization network to deliver advanced single-use devices to customers around the world. The offer will be reinforced by the production and research and development framework of Vedkang.
Flexible medical endoscopes and therapeutic devices are used in less invasive procedures.
The devices could benefit patients, physicians and healthcare systems by reducing the cost or complexity of procedures. It could also lead to improved recovery time for patients.
PENTAX Medical Global President Gerald Bottero said, “Our collaboration will support the rapidly growing endotherapy segment as new, innovative procedures achieve traction and penetration around the world.
“Now PENTAX Medical, together with Vedkang, is looking forward to offering integrated endoscopy solutions to our valued global customers. ”
With its headquarters in China, PENTAX Medical Therapeutics intends to develop and market products for major markets in Europe, Asia and the Americas.
Jiangsu Vedkang Medical Science and Technology Chairman and CEO Zhuang XiaoJing said, “PENTAX Medical has always been a valuable business partner for Vedkang, and we are delighted to continue our close relationship in this joint venture by pursuing new possibilities with doctors and patients around the world. ”
Last month, PENTAX Medical Europe received the CE mark for its latest single-use bronchoscope, PulmoONE, which provides high-quality care without risking the standard of pulmonary care.
PulmoONE’s working channel offers up to 50% increased suction power for fast and efficient patient care. It also offers greater sterility as well as high definition (HD) viewing, thus expanding its clinical uses beyond the traditional disposable scope, the company said.